RTTNews — Larimar Therapeutics, Inc. (LRMR) will host an investor event on Monday, June 29, 2026, at 7:45 a.m. ET to provide updates on its Nomlabofusp program for Friedreich’s ataxia.
Friedreich’s ataxia is a progressive, inherited neurodegenerative disorder that impairs coordination, mobility, and overall quality of life. Larimar’s lead compound, Nomlabofusp, is being developed as a potential therapy for both adults and children with the disease.
During the webcast, the company will share a regulatory update and data from the ongoing Phase 2 long‑term open‑label study of Nomlabofusp. Larimar also plans to leverage its intracellular delivery platform to design fusion proteins targeting other rare diseases characterized by deficiencies in intracellular bioactive compounds.
LRMR has traded between $2.71 and $6.42 over the past year. The stock closed Friday at $3.66, up 4.57 %. In after‑hours trading, the stock is at $4.00, up 9.29 %.
Also Read
- Pakistan Keeps Petrol and Diesel Prices Unchanged as US‑Iran Truce Stabilizes Oil Markets
- US-Iran Tensions Escalate with Military TensionsUS-Iran relations face heightened tensions following military confrontations. The US claims to have struck Iranian military sites, alleging Iranian forces targeted a vessel in the Strait of Hormuz. These developments occur despite a recently signed Memorandum of Understanding aimed at de-escalation.Published On 27 Jun 202627 Jun 2026
- US‑Mediated Framework Sets New Roadmap for Israel‑Lebanon Peace
- Uzbekistan’s Landmark IPO Signals Maturation of Emerging Capital Markets
